Low-dose alteplase appears optimal in patients with mild acute ischaemic stroke (AIS) and a favourable risk profile. A study led by the George Institute for Global Health used data from the international ENCHANTED study and a validation cohort from a South Korean stroke registry. The ENCHANTED data showed patients receiving the low 0.6mg/kg dose of ...
Already a member?
Enter your email to keep reading.